GlassScriptPhysician profile
Sage P Naran
NPI 1407971807
$3,047.00
in general payments reported to CMS, 2019-2025
31 companies · $18.85 in 2025
The $18.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $388 · 2021: $251 · 2022: $474 · 2023: $615 · 2024: $571 · 2025: $18.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.65 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,081.93 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $261.76 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $211.90 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $193.03 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $178.89 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $137.12 | 2023-2024 | |
| Exact Sciences Corporation | $125.85 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $123.04 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $108.03 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.31 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $57.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.66 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $52.83 | 2021-2022 | |
| Abbott Laboratories | $51.77 | 2022-2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $37.29 | 2023 | Sapien 3 Ultra Resilia |
| Shield Therapeutics INC | $27.16 | 2023 | Accrufer |
| Amneal Pharmaceuticals LLC | $23.48 | 2022 | |
| Esperion Therapeutics, INC. | $20.38 | 2024 | Nexletol |
| Vanda Pharmaceuticals INC. | $19.25 | 2022 | |
| Medtronic, INC. | $18.47 | 2024 | Intellis Adaptivestim |
| Mannkind Corporation | $17.04 | 2022 | |
| Allergan, INC. | $16.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2024 | Eliquis |
| Azurity Pharmaceuticals, INC. | $14.39 | 2023 | Horizant |
| Hologic Sales and Service, LLC | $13.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.49 | 2019 | |
| Dynavax Technologies Corporation | $12.86 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Currax Pharmaceuticals LLC | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sage Naran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.